Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Hydrocodone | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Magnesium sulfate | The therapeutic efficacy of Clidinium can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Clidinium may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Mirtazapine | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Orphenadrine | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Pramipexole | Clidinium may increase the sedative activities of Pramipexole. |
| Ropinirole | Clidinium may increase the sedative activities of Ropinirole. |
| Rotigotine | Clidinium may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Clidinium. |
| Sodium oxybate | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Thalidomide | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Clidinium is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Clidinium. |
| Mirabegron | The risk or severity of urinary retention can be increased when Clidinium is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Clidinium is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Clidinium. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Clidinium. |
| Tiotropium | The risk or severity of adverse effects can be increased when Clidinium is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Clidinium is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Clidinium is combined with Umeclidinium. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Clidinium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Clidinium is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type A. |
| Glucagon | Clidinium may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Clidinium may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Clidinium is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Clidinium is combined with Ramosetron. |
| Ethanol | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Clidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Clidinium is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Clidinium is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Clidinium is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Clidinium is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Clidinium is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Clidinium is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Clidinium is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Clidinium is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Clidinium is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Clidinium is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Clidinium is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of Tachycardia can be increased when Clidinium is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Clidinium is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Clidinium is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Clidinium is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Clidinium is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Clidinium is combined with Bezitramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Desomorphine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Nicomorphine. |
| Morphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Clidinium is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Clidinium is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Clidinium is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Clidinium is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Clidinium is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Clidinium is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Clidinium is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Clidinium is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Clidinium is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Clidinium is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Clidinium is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Clidinium is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Clidinium is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Clidinium is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Clidinium is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Clidinium is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Clidinium is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Clidinium is combined with Dextromoramide. |
| Carfentanil | The risk or severity of adverse effects can be increased when Clidinium is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Clidinium is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Clidinium is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Clidinium is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Clidinium is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Clidinium is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Clidinium is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Clidinium is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Clidinium is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Clidinium is combined with Piritramide. |